Results 81 to 90 of about 9,635 (207)

Personalised medicine of Cystic fibrosis [PDF]

, 2017
Treballs Finals de Grau de Farmàcia, Facultat de Farmàcia, Universitat de Barcelona, 2017. Tutor: Carlos Julián Ciudad i Gómez[en] The European commission defines personalised medicine as a medical approach that uses molecular insights into health and ...
Cabré Juan, Antoni
core  

Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? [PDF]

, 2014
Medicines have made an appreciable contribution to improving health. However, even high-income countries are struggling to fund new premium-priced medicines. This will grow necessitating the development of new models to optimize their use.
Acurcio, Francisco, Alkan, Ali, Brzezinska, Anna, Bucsics, Anna, Campbell, Stephen M, Czeczot, Jadwiga, de Bruyn, Winnie, Diogene, Eduardo, Eriksson, Irene, Finlayson, Alexander E, Fürst, Jurij, Garuoliene, Kristina, Godman, Brian, Gray, Andy, Guerra Júnior, Augusto, Gulbinovič, Jolanta, Gustafsson, Lars L, Jan, Saira, Jayathissa, Sisira, Joppi, Roberta, Kalaba, Marija, Magnisson, Einar, Malmström, Rickard E, McCullagh, Laura, Miikkulainen, Kaisa, Ofierska-Sujkowska, Gabriela, Pedersen, Hanne Bak, Selke, Gisbert, Sermet, Catherine, Spillane, Susan, Supian, Azuwana, Timoney, Angela, Truter, Ilse, Vien, Low Ee, Vlahović-Palčevski, Vera, Vural, Elif H, Wale, Janet, Władysiuk, Magdałene, Yusof, Faridah Aryani Md, Zeng, Wenjie   +39 more
core   +1 more source

Sodium Glucose‐Like Co‐Transporter 2 Inhibitor (SGLT2i) Use in Adults With Cystic Fibrosis

Respirology Case Reports, Volume 14, Issue 3, March 2026.
Use of sodium glucose‐like co‐transporter 2 inhibitors in people with cystic fibrosis may be considered for glycaemic, renal and cardiac benefits. We described safe, tolerable and effective use in three adults with CF. ABSTRACT Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) also called flozins or gliflozins have been demonstrated to have multi ...
Ellie Johnson, Angela Matson, Robyn Cobb, Shanal Kumar   +3 more
wiley   +1 more source

The use of Multiple Breath Washout for Assessing Cystic Fibrosis in Infants [PDF]

, 2016
INTRODUCTION: Lung Clearance Index, measured using the multiple breath washout (MBW) technique, may be a useful test in infants with Cystic Fibrosis (CF).
Aurora, P, Davies, G
core   +1 more source

Muscle Dysfunction and Bone Loss in a Woman With Cystic Fibrosis and Obesity Treated With Glucagon‐Like Peptide 1 Agonist: A Case Report

Respirology Case Reports, Volume 14, Issue 3, March 2026.
Cystic fibrosis (CF) modulator therapies can lead to rapid and excessive weight gain. Obesity in CF can lead to undesirable metabolic complications including type 2 diabetes. Therefore, glucagon‐like peptide 1 (GLP‐1) agonists which can facilitate weight loss and improve metabolic profiles are increasingly prescribed to people with CF.
Shanal Kumar, Robyn Cobb, Angela Matson, Joseph Lee, Daniel Henderson   +4 more
wiley   +1 more source

Ivacaftor ameliorates mucus burden, bacterial load, and inflammation in acute but not chronic P. aeruginosa infection in hG551D rats

Respiratory Research
Background Newly approved highly effective modulation therapies (HEMT) have been life-changing for people with CF. Although these drugs have resulted in significant improvements in lung function and exacerbation rate, bacterial populations in the lung ...
Johnathan D. Keith, Mikayla Murphree-Terry, Gretchen Bollar, Ashley M. Oden, Ian H. Doty, Susan E. Birket   +5 more
doaj   +1 more source

Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation [PDF]

European Respiratory Review, 2013
Cystic fibrosis (CF) is an autosomal recessive lethal disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that encodes for CFTR, an epithelial cell-surface expressed protein responsible for the transport of ...
Isabelle Sermet-Gaudelus
doaj  

A novel treatment of cystic fibrosis acting on-target:cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR [PDF]

, 2016
We previously reported that the combination of two safe proteostasis regulators, cysteamine and epigallocatechin gallate (EGCG), can be used to improve deficient expression of the cystic fibrosis transmembrane conductance regulator (CFTR) in patients ...
A Di Pasqua, A Luciani, A Luciani, A Mehta, A Sepe, A Tosco, A Venerando, AM Cantin, AM Jones, AMP Boyle, AS Verkman, B Bosch, B Illek, BW Ramsey, C A Leone, CE Wainwright, D Bilton, D De Stefano, D De Stefano, D Taylor-Robinson, DM Cholon, E Ferrari, F De Gregorio, F Emma, F Munkonge, F Ratjen, FJ Accurso, G Bona, G De Rosa, G Kroemer, G Stoll, G Veit, H Abdi, H Amano, H Corvol, H Fischer, I Sana, JH vanDoorninck, JL Jameson, JN Snouwaert, K De Boeck, K De Boeck, L Maiuri, L Maiuri, L Salvadori, LL Vanscoy, M C Maiuri, M Stern, MD Amaral, MD Amaral, MK Mansoura, ML DeMarco, NJ Schork, NT Awatade, P Buonpensiero, PB Davis, R Grassia, R Paine, RR Marchelletta, S Esposito, S Guido, S Jayaraman, S Lusa, V Gondzik, V Raia, VR Villella, WA Gahl, X Qu, X Wang   +68 more
core   +4 more sources

Obstetric and Neonatal Outcomes in Pregnancies From a Dedicated Cystic Fibrosis‐Maternal Health Service: A Retrospective Study

BJOG: An International Journal of Obstetrics &Gynaecology, Volume 133, Issue 4, Page 690-697, March 2026.
ABSTRACT Objective A comprehensive review of maternal, obstetric and neonatal outcomes in pregnancies in females with cystic fibrosis (fwCF) following the introduction of Elexacaftor/Tezacaftor/Ivacaftor (ETI) therapy in a novel, dedicated CF‐Maternal Health service.
Rebecca Scott, Amy Downes, Ladina Weitnauer, Rebecca Dobra, Natasha Singh, Rachel Robinson, Emily Diable, Saraha Collins, Elaine Bowman, Thomas Tobin, Andrew Jones, Nicholas Simmonds, Imogen Felton   +12 more
wiley   +1 more source

CFTR Modulator Therapy Enhances Peripheral Blood Monocyte Contributions to Immune Responses in People With Cystic Fibrosis

Frontiers in Pharmacology, 2020
BackgroundCFTR modulators decrease some etiologies of CF airway inflammation; however, data indicate that non-resolving airway infection and inflammation persist in individuals with CF and chronic bacterial infections.
Katherine B. Hisert, Katherine B. Hisert, Timothy P. Birkland, Kelly Q. Schoenfelt, Matthew E. Long, Brenda Grogan, Suzanne Carter, W. Conrad Liles, Edward F. McKone, Lev Becker, Anne M. Manicone, Sina A. Gharib   +11 more
doaj   +1 more source